NDAORALSUSPENSION
Approved
Jan 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VARIBAR THIN HONEY (barium sulfate) by Bracco is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 2016.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VARIBAR THIN HONEY is an oral barium sulfate suspension used as a radiographic contrast agent for diagnostic imaging procedures. It enables visualization of the gastrointestinal tract during X-ray examinations by providing radiopaque contrast. The product works through X-ray contrast activity, allowing clinicians to detect structural abnormalities in swallowing and GI anatomy.
Peak
Product is in peak commercial phase under Bracco's dominant portfolio of barium contrast agents, suggesting stable team size and mature marketing operations.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Career Relevance
Working on VARIBAR THIN HONEY offers stable, predictable roles in a mature diagnostic imaging portfolio within Bracco's established market leadership. Career progression emphasizes commercial execution, account management, and operational excellence rather than breakthrough innovation or clinical expansion.
Worked on VARIBAR THIN HONEY at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.